logo

EVOK(Delisted)

Evoke Pharma·NASDAQ
--
--(--)
3.25 / 10
Netural

Fundamentals score 3.2/10 (Neutral). Strengths: Cash-MV and Days sales outstanding. Weaknesses: Income tax/Total profit and Asset-MV. Mixed factor performance and low score justify a prudent, cautious stance.

Fundamental(3.25)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value0.68
Score2/3
Weight18.32%
1M Return7.85%
Total operating revenue (YoY growth rate %)
Value60.15
Score2/3
Weight1.96%
1M Return1.07%
Days sales outstanding
Value68.14
Score3/3
Weight3.41%
1M Return1.75%
Inventory turnover ratio
Value0.60
Score2/3
Weight0.34%
1M Return0.18%
Gross profit margin (%)
Value97.20
Score2/3
Weight4.44%
1M Return2.08%
PB-ROE
Value-0.58
Score3/3
Weight29.92%
1M Return13.94%
Income tax / Total profit (%)
Value-5.84
Score0/3
Weight-1.74%
1M Return-1.01%
Cost of sales ratio (%)
Value2.80
Score3/3
Weight3.26%
1M Return1.56%
Asset-MV
Value-0.45
Score0/3
Weight17.33%
1M Return6.96%
Cash-MV
Value0.44
Score2/3
Weight22.75%
1M Return9.82%
Is EVOK undervalued or overvalued?
  • EVOK scores 3.25/10 on fundamentals and holds a Fair valuation at present. Backed by its -77.56% ROE, -36.23% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 86.39% earnings growth, these metrics solidify its Netural investment rating.